🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AirSculpt Technologies, Inc. AIRS R2K

Healthcare · Medical Care Facilities · United States
https://www.airsculpt.com
Company Profile ↓
$4.20
-19.85% 1Y
Mkt Cap$296.29M
P/E-24.71
P/B3.76
52W High$11.65
52W Low$1.58
Book Value$1.42
EPS (TTM)$-0.17

Company Overview

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $151.82M (-15.8% YoY); net profit $-11.67M.
  • Trailing 12 Months Year-on-year growth — revenue +0.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -3.5%, profit CAGR 6.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-3.47%
1 Year:0.00%

Compounded Profit Growth

5 Years:6.84%
1 Year:-

Stock Price Performance

1 Year:-19.85%
6 Months:+85.84%
3 Months:+56.13%
1 Month:-21.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 26% of range
$1.58 $11.65
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Golden Cross10d ago
  • RSI (14)39.86 · Neutral
Price Performance
1M-21.50%
3M+56.13%
6M+85.84%
1Y-19.85%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -3.5% CAGR over 5 years.
  • Trading 64.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-24.71
Industry PE
25.41
Forward P/E
-210.00
PEG Ratio
-
Book Value
$1.42
Price to Book
3.76
P/S
2.49
EV/EBITDA
57.46
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-3.47%
Profit 5Y
6.84%
Revenue (YoY)
0.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-7.25%
ROE
-12.63%
ROA
-1.60%
Profit Margin
-7.39%
Op Margin
-4.58%
Gross Margin
66.06%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.17

Balance Sheet & Liquidity

Debt/Equity
0.71
Quick Ratio
0.57
Current Ratio
0.75
Debt
$71.02M
Total Assets
$192.00M
Current Assets
$24.33M
Working Capital
$-12.45M

Ownership

Promoter Holding
43.06%
Chg in Prom Hold
-
FII / Inst Holding
66.03%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$296.29M
Total Revenue (TTM)
$151.84M
EBITDA
$7.51M
Free Cash Flow
$13.02M
Operating Cash Flow
$7.50M
Shares Outstanding
70.55M
Gross Margin
66.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AIRS AirSculpt Technologies, Inc. R2K 4.20 -24.71 $296.29M 0.00% -7.25% -12.63% -3.47% 6.84%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 26.14M34.97M34.65M-39.54M49.65M38.89M45.81M55.70M46.79M47.62M51.00M--39.37M44.01M34.99M33.44M39.39M
Cost of Revenue --------------15.95M17.20M14.86M13.68M15.59M
Gross Profit --------------23.42M26.81M20.13M19.77M23.80M
Operating Expenses --------------25.01M25.92M22.74M21.29M25.60M
Operating Income 7.21M11.20M9.62M--1.17M3.96M-1.38M1.76M5.36M955.00K11.01M-4.98M---1.59M894.00K-2.61M-1.52M-1.80M
EBITDA --------------1.65M4.03M-6.53M2.07M1.36M
Interest Expense --------------1.62M1.56M1.41M1.48M1.20M
Pretax Income ---------------3.21M-776.00K-11.16M-2.49M-2.86M
Tax Provision ---------------367.00K-185.00K-1.65M-3.77M-465.00K
Net Income 6.62M10.03M8.05M-393.00K-693.00K583.00K-7.38M-14.00K1.78M-1.67M6.03M-3.21M---2.85M-591.00K-9.51M1.28M-2.40M
Diluted EPS -----0.010.01-0.130.000.03-0.030.10-0.06---0.05-0.01-0.150.02-0.03

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 41.24M62.77M-168.79M195.92M180.35M151.82M
Cost of Revenue ---62.78M73.77M71.15M61.69M
Gross Profit ---106.01M122.14M109.20M90.13M
Operating Expenses ---109.48M112.63M110.77M94.96M
Operating Income 663.00K10.03M--3.47M9.51M-1.57M-4.83M
EBITDA ---3.52M19.98M10.30M1.22M
Interest Expense ---6.75M6.49M6.25M6.08M
Pretax Income ----11.30M3.24M-7.83M-17.64M
Tax Provision ---3.38M7.48M188.00K-5.97M
Net Income -2.21M7.58M--14.68M-4.24M-8.02M-11.67M
Diluted EPS ----0.26-0.08-0.14-0.19

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 179.61M-200.76M204.02M212.78M187.30M
Current Assets --16.68M15.96M17.12M15.46M
Cash & Equivalents 10.38M-9.62M10.26M8.23M8.45M
Inventory ------
Receivables --2.83M1.94M3.06M1.50M
Total Liabilities 55.93M-129.99M120.03M134.59M99.59M
Current Liabilities 9.46M-22.32M20.32M28.95M27.90M
Long Term Debt 32.12M-81.42M69.50M70.46M50.59M
Total Debt --107.65M99.67M108.94M83.57M
Total Equity --70.77M83.99M78.19M87.71M
Shares Outstanding --56.18M57.36M58.37M64.54M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 4.94M13.96M-24.45M23.96M11.35M3.10M
Investing Cash Flow -4.44M-3.69M--12.92M-9.92M-14.01M-2.40M
Financing Cash Flow -783.00K-5.02M--27.26M-13.39M630.00K-478.00K
Capital Expenditure -4.44M-3.69M--12.92M-9.92M-14.01M-2.40M
Free Cash Flow 499.00K10.27M-11.53M14.04M-2.66M692.00K
Net Change in Cash ----15.73M646.00K-2.03M214.00K
Dividends Paid -0023.16M385.00K252.00K0

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---62.8%62.3%60.5%59.4%
Operating Margin % 1.6%16.0%--2.1%4.9%-0.9%-3.2%
Net Margin % -5.4%12.1%--8.7%-2.2%-4.4%-7.7%
ROE % ----20.7%-5.0%-10.3%-13.3%
ROCE % -5.9%--1.9%5.2%-0.9%-3.0%

Shareholding Pattern

Insiders
43.06%
Institutions
66.03%
Public Float
115.98%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vesey Street Capital Partners, LLC 42.99% 30.32M $136.19M
2 Balyasny Asset Management LP 3.30% 2.33M $10.45M
3 FourWorld Capital Management, LLC 1.40% 987.76K $4.44M
4 Blackrock Inc. 1.14% 804.08K $3.61M
5 Wexford Capital LP 0.95% 670.52K $3.01M
6 UBS Group AG 0.88% 622.29K $2.79M
7 Susquehanna International Group, LLP 0.67% 474.44K $2.13M
8 Geode Capital Management, LLC 0.52% 368.46K $1.65M
9 Saba Capital Management, L.P. 0.44% 313.04K $1.41M
10 AQR Capital Management, LLC 0.44% 309.33K $1.39M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AIRS

Yahoo Finance Wed, 27 May 2026

AirSculpt Technologies Announces Participation in Upcoming Investor Conferences

MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced that the Company will par…

Yahoo Finance ue, 19 May 2026

AirSculpt Technologies Sees Sales Rebound, GLP-1 Tailwind for Body Contouring Growth

AirSculpt Technologies (NASDAQ:AIRS) executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side eff…

Yahoo Finance Fri, 08 May 2026

AirSculpt Technologies Q1 Earnings Call Highlights

AirSculpt Technologies (NASDAQ:AIRS) reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and conti…

Yahoo Finance Fri, 08 May 2026

AirSculpt Technologies Reports First Quarter Fiscal 2026 Results

Same Center Sales Increase 1% and Reaffirms Fiscal Year 2026 OutlookMIAMI BEACH, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring…

Yahoo Finance Fri, 01 May 2026

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results

Company to Participate in Upcoming Investor ConferencesMIAMI BEACH, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring…

Yahoo Finance Mon, 06 Apr 2026

CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

MIAMI BEACH, Fla., April 06, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 2nd, 2026, by AirSculpt Technologies, Inc. (NASDAQ:AIRS), please note that the Company determined that a one-time non-cash adjustment…

AIRS — Frequently Asked Questions

What is the current share price of AirSculpt Technologies, Inc. (AIRS)?

As of 2026-07-14 21:23 PDT, AirSculpt Technologies, Inc. (AIRS) trades at $4.20 on NasdaqGM. Its 52-week range is $1.58 to $11.65.

What is the market capitalisation of AIRS?

AirSculpt Technologies, Inc. (AIRS) has a market capitalisation of $296.29M on NasdaqGM.

What is the P/E ratio of AIRS?

AIRS trades at a trailing price-to-earnings (P/E) ratio of -24.71. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.76.

What is the return on equity (ROE) of AIRS?

AIRS has a return on equity (ROE) of -12.63%. Its return on capital employed (ROCE) is -7.25%.

Is AIRS a good stock to buy?

This page provides a data-driven analysis of AirSculpt Technologies, Inc. (AIRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space